Mizuki Y, Kajimura N, Imai T, Suetsugi M, Kai S, Kaneyuki H, Yamada M
Department of Neuropsychiatry, Yamaguchi University School of Medicine, Ube, Japan.
Int Clin Psychopharmacol. 1990 Apr;5(2):83-95. doi: 10.1097/00004850-199004000-00002.
The efficacy of mianserin as a supplement in treating chronic schizophrenia was tested in 20 inpatients with schizophrenia who were receiving fixed doses of neuroleptics. Mianserin was given for six weeks with a starting dose of 60 mg/day. A brief psychiatric rating scale (BPRS) was completed before starting mianserin and thereafter BPRS scoring was carried out once weekly. The total BPRS score and the score for negative symptoms were decreased by mianserin treatment as compared to the pre-treatment values. Plasma 5-HIAA concentrations were increased after medication in both responding patients and nonresponding patients. However, the 5-HIAA values of responders were lower than those of nonresponders. Plasma HVA levels were slightly increased by mianserin in the responders. There were no significant changes in MHPG levels. These results suggest that the negative symptoms of schizophrenia may be improved by mianserin treatment.
对20名正在接受固定剂量抗精神病药物治疗的精神分裂症住院患者，测试了米安色林作为辅助药物治疗慢性精神分裂症的疗效。米安色林剂量从60毫克/天开始，服用六周。在开始服用米安色林之前完成一份简短的精神病评定量表（BPRS），之后每周进行一次BPRS评分。与治疗前相比，米安色林治疗使BPRS总分及阴性症状评分降低。无论是有反应的患者还是无反应的患者，用药后血浆5-羟吲哚乙酸（5-HIAA）浓度均升高。然而，有反应患者的5-HIAA值低于无反应患者。米安色林使有反应患者的血浆高香草酸（HVA）水平略有升高。3-甲氧基-4-羟基苯乙二醇（MHPG）水平无显著变化。这些结果表明，米安色林治疗可能改善精神分裂症的阴性症状。
Zotero 插件